Liu Shu-Yan, Wang Hong, Wang Ting, Zhou Lin-Fei, Xu Xiao-Li, Hou Baohua, Yang Bo, Sun Li-Sha, Pang Hui, Wang Hui-Hui, Chen Jie
Department of Endocrinology, The First Affiliated Hospital of Henan Polytechnic University (The Second People's Hospital of Jiaozuo), Jiaozuo, China.
Department of Endocrinology, The First Affiliated Hospital of Henan Polytechnic University (The Second People's Hospital of Jiaozuo), Democratic South Road 17, Jiefang District, Jiaozuo, 454000, China.
J Endocrinol Invest. 2025 Jul 9. doi: 10.1007/s40618-025-02647-9.
Graves' ophthalmopathy (GO), a common extrathyroidal manifestation of Graves' disease, is characterized by inflammation and tissue remodeling in the orbit. Hyaluronan synthase 2 (HAS2) plays a pivotal role in hyaluronan (HA) production, which is implicated in the pathophysiology of GO. Understanding the regulatory mechanisms of HAS2 could provide novel therapeutic targets for managing this debilitating condition.
The study treated human orbital fibroblasts with platelet-derived growth factor BB (PDGF-BB) to mimic an in vitro GO model. Methyltransferase like 3 (METTL3) inhibitor, STM2457, was used to analyze METTL3-induced effects on PDGF-BB-induced HA production and proliferation in human orbital fibroblasts. Quantitative real-time PCR (qRT-PCR) and western blotting assays were performed to assess mRNA and protein expressions, respectively. HA concentration was measured using a colorimetric assay. Cell viability was analyzed using a cell counting kit-8 (CCK-8) assay. Cell proliferation was evaluated using a 5-Ethynyl-2'-deoxyuridine (EdU) assay. The interactions between HAS2 and METTL3, YTH N6-methyladenosine RNA binding protein 1 (YTHDF1), and activating transcription factor 6 (ATF6) were investigated using RNA immunoprecipitation assay, m6A methylated RNA immunoprecipitation assay, dual-luciferase reporter assay, and/or chromatin immunoprecipitation assay.
HAS2 and ATF6 expression levels were upregulated in PDGF-BB-induced human orbital fibroblasts, whereas METTL3 expression was downregulated. Knockdown of HAS2 reduced PDGF-BB-induced HA production and proliferation in human orbital fibroblasts. METTL3 was found to destabilize HAS2 mRNA through m6A modification and promote its degradation in a YTHDF1-dependent manner. Treatment with STM2457 enhanced PDGF-BB-induced effects. In addition, METTL3 overexpression attenuated PDGF-BB-induced HA production and proliferation of human orbital fibroblasts by regulating HAS2. The results also showed that ATF6 transcriptionally activated HAS2, and HAS2 overexpression counteracted the effects of ATF6 knockdown on HA production and proliferation of PDGF-BB-stimulated human orbital fibroblasts.
METTL3 overexpression and ATF6 silencing led to an inhibition in HAS2 expression, which in turn mitigated PDGF-BB-induced hyaluronan production and the proliferation of human orbital fibroblasts in GO. These findings offer a new avenue for the development of targeted therapies.
格雷夫斯眼病(GO)是格雷夫斯病常见的甲状腺外表现,其特征为眼眶炎症和组织重塑。透明质酸合酶2(HAS2)在透明质酸(HA)生成中起关键作用,而HA与GO的病理生理学有关。了解HAS2的调控机制可为治疗这种使人衰弱的疾病提供新的治疗靶点。
本研究用血小板衍生生长因子BB(PDGF-BB)处理人眼眶成纤维细胞以模拟体外GO模型。使用甲基转移酶样3(METTL3)抑制剂STM2457分析METTL3对PDGF-BB诱导的人眼眶成纤维细胞HA生成和增殖的影响。分别进行定量实时PCR(qRT-PCR)和蛋白质印迹分析以评估mRNA和蛋白质表达。使用比色法测定HA浓度。使用细胞计数试剂盒-8(CCK-8)分析评估细胞活力。使用5-乙炔基-2'-脱氧尿苷(EdU)分析评估细胞增殖。使用RNA免疫沉淀分析、m6A甲基化RNA免疫沉淀分析、双荧光素酶报告基因分析和/或染色质免疫沉淀分析研究HAS2与METTL3、YTH N6-甲基腺苷RNA结合蛋白1(YTHDF1)和活化转录因子6(ATF6)之间的相互作用。
在PDGF-BB诱导的人眼眶成纤维细胞中,HAS2和ATF6表达水平上调,而METTL3表达下调。敲低HAS2可减少PDGF-BB诱导的人眼眶成纤维细胞中HA的生成和增殖。发现METTL3通过m6A修饰使HAS2 mRNA不稳定,并以YTHDF1依赖的方式促进其降解。用STM2457处理可增强PDGF-BB诱导的作用。此外,METTL3过表达通过调节HAS2减弱PDGF-BB诱导的人眼眶成纤维细胞中HA的生成和增殖。结果还表明,ATF6转录激活HAS2,HAS2过表达抵消了ATF6敲低对PDGF-BB刺激的人眼眶成纤维细胞中HA生成和增殖的影响。
METTL3过表达和ATF6沉默导致HAS2表达受到抑制,进而减轻了PDGF-BB诱导的GO中透明质酸生成和人眼眶成纤维细胞的增殖。这些发现为开发靶向治疗提供了新途径。